Document:

EX-4.3

 Exhibit 4.3 

THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE
“ACT”) OR THE SECURITIES LAWS OF ANY STATE, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW OR, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF, AND MAY BE OFFERED, SOLD, ASSIGNED, PLEDGED, TRANSFERRED OR OTHERWISE
DISPOSED OF IN THE UNITED STATES ONLY PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT OR PURSUANT TO AN APPLICABLE EXEMPTION FROM REGISTRATION UNDER THE ACT AND, IF REQUESTED, BY GENOMEDX BIOSCIENCES INC. (THE “COMPANY”),
UPON DELIVERY OF AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE ACT. 

THIS WARRANT AND THE UNDERLYING SECURITIES EVIDENCED HEREBY ARE SUBJECT TO A VOTING AGREEMENT, AS MAY BE AMENDED FROM TIME TO TIME, (A COPY
OF WHICH MAY BE OBTAINED ;UPON WRITTEN REQUEST FROM THE COMPANY), AND BY ACCEPTING ANY INTEREST IN SUCH WARRANT AND THE UNDERLYING SECURITIES EVIDENCED HEREBY THE PERSON ACCEPTING SUCH INTEREST SHALL BE DEEMED TO AGREE AND SHALL BECOME BOUND BY ALL
THE PROVISIONS OF THAT VOTING AGREEMENT, INCLUDING CERTAIN RESTRICTIONS ON TRANSFER AND OWNERSHIP SET FORTH THEREIN. 
 GENOMEDX
BIOSCIENCES INC. 
 WARRANT TO PURCHASE COMMON SHARES 
  

			
	 No. W-1
	  	February 1, 2013

 Void After January 31, 2023 

THIS WARRANT CERTIFIES THAT, for value
received, MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH, a Minnesota charitable corporation (the “Holder”) is entitled, subject to the terms and conditions hereinafter set forth, to subscribe for and purchase from
GENOMEDX BIOSCIENCES INC., a corporation with its principal office at 311 Water Street, 4th Floor, Vancouver, B.C., Canada, V6B 1B8 (the
“Company”) one million six-hundred and seventy-five thousand (1,675,000) Class A common shares in the capital of the Company, subject to adjustment pursuant to the terms herein, including
but not limited to adjustment pursuant to Section 6 below (the “Exercise Shares”). 
 This Warrant is being
issued pursuant to the terms of that certain Patent and Know-How License Agreement dated February 1, 2013, by and among the Company and the Holder. 

1.    EXERCISE PRICE. As used herein, the term “Exercise Price”
shall mean One Dollar and Fourteen Cents ($1.14) in United States currency, per Exercise Share, subject to adjustment pursuant to Section 6 below. 

2.    TERM OF WARRANT. This Warrant shall terminate on
January 31, 2023, being the date that is ten (10) years following the date of issuance (the “Expiry Time”). 

3.    EXERCISE OF WARRANT. Unless a net exercise is made
pursuant to the terms of Section 3 hereof, the rights represented by this Warrant may be exercised in whole or in part at any time prior to the Expiry 

 
Time, by delivery of the following to the Company at its address set forth above (or at such other address as it may designate by notice in writing to the Holder): 

(a)    An executed Notice of Exercise in the form attached hereto; 

(b)    Payment of the Exercise Price either (i) in cash or by check, or (ii) by
cancellation of indebtedness; and 
 (c)    This Warrant. 

Upon the exercise of the rights represented by this Warrant, a certificate or certificates for the Exercise Shares so
purchased, registered in the name of the Holder, or its assigns, if the Holder so designates, shall be issued and delivered to the Holder within a reasonable time after the rights represented by this Warrant shall have been so exercised. 

The person in whose name any certificate or certificates for Exercise Shares are to be issued upon exercise of this Warrant
shall be deemed to have become the holder of record of such shares on the date on which this Warrant was surrendered and payment of the Exercise Price was made, irrespective of the date of delivery of such certificate or certificates, except that,
if the date of such surrender and payment is a date when the securities registers of the Company are closed, such person shall be deemed to have become the holder of such shares at the close of business on the next succeeding date on which the
securities registers are open. 
 4.    NET EXERCISE. Notwithstanding any
provisions herein to the contrary, if the fair market value of one Exercise Share is greater than the Exercise Price (at the date of calculation as set forth below), in lieu of exercising this Warrant by payment of cash, the Holder may elect to
exercise this Warrant on a net basis, by surrender of this Warrant at the principal office of the Company (or at such other place or places as may be determined by the Company from time to time) together with the properly endorsed Notice of
Exercise, in which event the Company shall issue to the Holder a number of Exercise Shares computed using the following formula: 
  

			
	 X =
	  	 Y (A-B)

		  	       A

  

					
	 Where
	 	 X =
	 	 the number of Exercise Shares to be issued to the Holder

			
		 	 Y =
	 	 the number of Exercise Shares purchasable under the Warrant or, if only a portion of the Warrant is being exercised, the
number of Exercise Shares purchasable under the portion of the Warrant so exercised (at the date of such calculation)

			
		 	 A =
	 	 the fair market value of one Exercise Share (at the date of such calculation)

			
		 	 B =
	 	 Exercise Price (as adjusted to the date of such calculation)

 For purposes of the above calculation and section 9 hereof, the fair market value of one
Exercise Share shall be determined by the Company’s Board of Directors in good faith; provided, however, that in the event that this Warrant is exercised pursuant to this Section 3 in connection with the Company’s initial public
offering of its Class A common shares (“Common Shares”), the fair market value per Exercise Share shall be the per Common Share offering price to the public of the Company’s initial public offering. 

  
 - 2 - 

 5.    COVENANTS OF
THE COMPANY. 
 5.1    Covenants as to Exercise Shares.
The Company covenants and agrees that all Exercise Shares that may be issued upon the exercise of the rights represented by this Warrant will, upon issuance, be validly issued and outstanding, fully paid and nonassessable, and free from all taxes,
liens and charges with respect to the issuance thereof. The Company further covenants and agrees that the Company will at all times prior to the Expiry Time, have authorized and reserved, free from preemptive rights, a sufficient number of Common
Shares to provide for the exercise of the rights represented by this Warrant. If at any time prior to the Expiry Time the number of authorized but unissued Common Shares shall not be sufficient to permit exercise of this Warrant, the Company
will take such corporate action as may, in the opinion of its counsel, be necessary to increase its authorized but unissued Common Shares to such number of shares as shall be sufficient for such purposes. 

5.2    No Impairment. Except and to the extent as waived or consented to by the Holder, the
Company will not, by amendment of its Articles of Amendment or Notice of Articles or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to
avoid the observance or performance of any of the terms to be observed or performed hereunder by the Company, and the board of directors of the Company shall have the power and authority to determine, in their sole discretion and acting in good
faith, the manner in which the provisions of this Warrant will be carried out and the actions to be taken in order to give effect to and preserve the rights of the Holder under this Warrant. 

5.1    Notices of Record Date. In the event of any taking by the Company of a record
of the holders of any class of securities for the purpose of determining the Holders thereof who are entitled to receive any dividend (other than a cash dividend which is the same as cash dividends paid in previous quarters) or other
distribution, the Company shall mail to the Holder, at least five (5) days prior to the record date therefor, a notice specifying the date on which any such record is to be taken for the purpose of such dividend or distribution. 

6.    REPRESENTATIONS OF HOLDER. 

6.1    Acquisition of Warrant for Personal Account. The Holder represents and warrants that
it is acquiring the Warrant and, upon exercise, will acquire the underlying Exercise Shares solely for its account for investment purposes and not with a view to or for sale or distribution of said Warrant or Exercise Shares or any part thereof. The
Holder also represents that the entire legal and beneficial interests of the Warrant and Exercise Shares the Holder is acquiring is being acquired for, and will be held for, its account only. 

6.2    Disclosure of Information. Holder has received or has had full access to all the
information it considers necessary or appropriate to make an informed investment decision with respect to the acquisition of this Warrant and its underlying securities. Holder further has had an opportunity to ask questions and receive answers from
the Company regarding the terms and conditions of the offering of this Warrant and its underlying securities and to obtain additional information (to the extent the Company possessed such information or could acquire it without unreasonable effort
or expense) necessary to verify any information furnished to Holder or to which Holder has access. 

6.3    Investment Experience. Holder understands that the purchase of this Warrant and its
underlying securities involves substantial risk. Holder has experience as an investor in securities of companies in the development stage and acknowledges that Holder can bear the economic risk of such Holder’s investment in this Warrant and
its underlying securities and has such knowledge and experience in financial or business matters that Holder is capable of evaluating the merits and risks of its investment in this 

  
 - 3 - 

 
Warrant and its underlying securities and/or has a preexisting personal or business relationship with the Company and certain of its officers, directors or controlling persons of a nature and
duration that enables Holder to be aware of the character, business acumen and financial circumstances of such persons. 

6.4    Accredited Investor Status. Holder is an “accredited investor” within the
meaning of Regulation D promulgated under the United States Securities Act of 1933, as amended (the “Act”) and an “accredited investor” as that term is defined in National Instrument 45-106
Prospectus and Registration Exemptions (“NI 45-106”), as Holder is a person that has net assets of at least CAD $5,000,000 as shown on its most recently prepared financial statements. 

6.5    Securities Are Not Registered. 

(a)    The Holder understands that the Warrant and the Exercise Shares issuable upon the exercise
of this Warrant have not been and will not be registered under the Act or any state securities laws or qualified by prospectus under Canadian securities laws on the basis that no distribution or public offering of the Common Shares of the Company is
to be effected. The Holder realizes that the basis for the exemption may not be present if, notwithstanding its representations, the Holder has a present intention of acquiring the securities for a fixed or determinable period in the future, selling
(in connection with a distribution or otherwise), granting any participation in, or otherwise distributing the securities. The Holder has no such present intention. 

(b)    The Holder recognizes that the Warrant and the Exercise Shares are subject to restrictions
on transfer and are “restricted securities” under applicable United States and Canadian securities laws and must be held indefinitely unless they are subsequently registered under the Act and qualified by state authorities or qualified by
prospectus under Canadian securities laws or an exemption from such registration and qualification requirements is available. The Holder recognizes that the Company has no obligation to register and qualify the Warrant or the Exercise Shares, or to
comply with any exemption from such registration and qualification requirements. 
 (c)    The
Holder recognizes that if an exemption from registration or qualification is available, it may be conditioned on various requirements including, but not limited to, the time and manner of sale, the hold period for the Warrant or Exercise Shares
issuable upon exercise of the Warrant, the availability of certain public information about the Company, and on requirements relating to the Company which are outside of the Holder’s control, and which the Company is under no obligation and may
not be able to satisfy. The Holder understands that the Securities and Exchange Commission has expressed its opinion that persons proposing to sell restricted securities received in a private offering other than in a registered offering will have a
substantial burden of proof in establishing that an exemption from registration is available for such offers or sales and that such persons and brokers who participate in the transactions do so at their own risk. 

6.6    Disposition of Warrant and Exercise Shares. 

(a)    The Holder further agrees not to make any disposition of all or any part of the Warrant or
Exercise Shares in any event unless and until: 
 (i)    The Company shall have received a letter
secured by the Holder from the Securities and Exchange Commission stating that no action will be recommended to the Securities and Exchange Commission with respect to the proposed disposition; 

  
 - 4 - 

 (ii)    There is then in effect a registration
statement under the Act or a prospectus under Canadian securities laws covering such proposed disposition and such disposition is made in accordance with said registration statement or prospectus; or 

(iii)    The Holder shall have notified the Company of the proposed disposition and shall have
furnished the Company with a detailed statement of the circumstances surrounding the proposed disposition, and if reasonably requested by the Company, the Holder shall have furnished the Company with an opinion of counsel, reasonably satisfactory to
the Company, for the Holder to the effect that such disposition will not require registration of such Warrant or Exercise Shares under the Act or any applicable state securities laws or qualification of such Warrant or Exercise Shares by prospectus
under Canadian securities laws. 
 (b)    The Holder understands and agrees that all certificates
evidencing the Exercise Shares to be issued to the Holder may bear the following legend: 
 THESE SECURITIES HAVE NOT BEEN
REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”) OR THE SECURITIES LAWS OF ANY STATE, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW OR, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF,
AND MAY BE OFFERED, SOLD, ASSIGNED, PLEDGED, TRANSFERRED OR OTHERWISE DISPOSED OF IN THE UNITED STATED ONLY PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT OR PURSUANT TO AN APPLICABLE EXEMPTION FROM REGISTRATION UNDER THE ACT AND, IF
REQUESTED, BY GENOMEDX BIOSCIENCES INC. (THE “COMPANY”), UPON DELIVERY OF AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE ACT. 

THE SHARES EVIDENCED HEREBY ARE SUBJECT TO A VOTING AGREEMENT, AS MAY BE AMENDED FROM TIME TO TIME, (A COPY OF WHICH MAY BE
OBTAINED UPON WRITTEN REQUEST FROM THE COMPANY), AND BY ACCEPTING ANY INTEREST IN SUCH SHARES THE PERSON ACCEPTING SUCH INTEREST SHALL BE DEEMED TO AGREE AND SHALL BECOME BOUND BY ALL THE PROVISIONS OF THAT VOTING AGREEMENT, INCLUDING CERTAIN
RESTRICTIONS ON TRANSFER AND OWNERSHIP SET FORTH THEREIN. 
 7.    ADJUSTMENT OF
EXERCISE PRICE. In the event of changes in the outstanding Common Shares of the Company by reason of stock dividends, stock splits, recapitalizations, reclassifications, consolidations, combinations or exchanges of
shares, separations, reorganizations, liquidations, or the like (each, an “Event”), at any time prior to the Expiry Time, the number and class of shares available under the Warrant in the aggregate and the Exercise Price shall be
correspondingly adjusted to give the Holder of the Warrant, on exercise for the same aggregate Exercise Price, the total number, class, and kind of shares as the Holder would have owned had the Warrant been exercised prior to the Event and had the
Holder continued to hold such shares until after the Event requiring adjustment; provided, however, that such adjustment shall not be made with respect to, and this Warrant shall terminate if not exercised prior to, the events set forth in
Section 9 below. The form of this Warrant need not be changed because of any adjustment in the number of Exercise Shares subject to this Warrant. 

  
 - 5 - 

 8.    FRACTIONAL SHARES.
Notwithstanding any provisions to the contrary herein, no fractional Exercise Shares shall be issued in connection with the exercise of this Warrant, whether as a consequence of any adjustment pursuant hereto or under any other circumstances.
All Exercise Shares (including fractions) issuable upon exercise of this Warrant shall be aggregated for purposes of determining whether the exercise would result in the issuance of any fractional Exercise Share, and the Company shall be required to
issue the largest number of whole Exercise Shares in respect of which the Warrant is exercised. The Company shall not pay any amounts to the Holder in satisfaction of the right to otherwise have received a fraction of an Exercise Share. 

9.    EARLY TERMINATION; DEEMED EXERCISE. In the
event of, at any time prior to the Expiry Time, an initial public offering of securities of the Company registered under the Act or qualified by prospectus under Canadian securities laws, or any capital reorganization, or any reclassification of the
Common Shares of the Company (other than a change in par value or from par value to no par value or no par value to par value or as a result of a stock dividend or subdivision, split-up or combination of
shares), or the consolidation or merger of the Company with or into another corporation (other than a merger solely to effect a reincorporation of the Company into another state), or the sale or other disposition of all or substantially all the
undertaking of the Company to any other person (each, a “Termination Event”), the Company shall provide to the Holder ten (10) days advance written notice of such Termination Event. If the fair market value of one Exercise Share is
greater than the Exercise Price as of the consummation of such Termination Event, then this Warrant shall be deemed automatically net exercised pursuant to Section 3 immediately prior to the consummation of such Termination Event, unless the
Holder notifies the Company in writing to the contrary prior to such automatic exercise. If the fair market value of one Exercise Share is equal or less than the Exercise Price as of the consummation of such Termination Event, then this Warrant
shall terminate and be of no further force or effect upon the closing of such Termination Event. 

10.    MARKET STAND-OFF
AGREEMENTS. Holder shall not sell, dispose of, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale, any Exercise Shares
(or other securities) of the Company held by Holder, for a period of time specified by the managing underwriter(s) (not to exceed one hundred eighty (180) days) (the “Lock-Up Period”) following
the effective date of a registration statement of the Company filed under the Act or a prospectus of the Company filed pursuant to Canadian securities laws. Holder agrees to execute and deliver such other agreements as may be reasonably requested by
the Company and/or the managing underwriter(s) which are consistent with the foregoing or which are necessary to give further effect thereto. Holder further agrees that, following expiration of the Lock-Up
Period, it will not sell any Exercise Shares (or other securities) of the Company held by Holder or its affiliates in excess of the volume limitations imposed on affiliates of the Company by Rule 144(e) as adopted under the Act (or the successor to
such rule), regardless of whether the Holder is an “affiliate” of the Company for purposes of such rule. In order to enforce the foregoing covenants, the Company may impose stop-transfer instructions with respect to such Exercise Shares
(or other securities) until the end of such period. The underwriters of the Company’s securities are intended third party beneficiaries of this Section 10 (as it pertains to the Lock-Up Period) and
shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. 

11.    ADOPTION AGREEMENT. Pursuant to section 5.1(b) of the
Voting Agreement entered into on December 2, 2011 (the “Voting Agreement”) between the Company, certain investors and shareholders, the parties hereto acknowledge and agree that it is a condition precedent to the entering into this
Warrant and the issuance of the Exercise Shares issuable hereunder that Holder execute and deliver to the Company, concurrent with the execution and delivery of this Warrant, an adoption agreement (the “Adoption Agreement’“), in the
form attached hereto as Schedule A, pursuant to which the Holder shall agree to be a party to and bound by the terms of the Voting Agreement and the Holder hereby covenants and agrees to execute and deliver the Adoption Agreement to the Company
concurrent with the execution and delivery of this Warrant. 

  
 - 6 - 

 12.    NO SHAREHOLDER
RIGHTS. This Warrant in and of itself shall not entitle the Holder to any voting rights or other rights as a shareholder of the Company. 

13.    TRANSFER OF WARRANT. This Warrant and all rights
hereunder may not be transferred or assigned, and any such purported transfer or assignment shall be void. 

14.    LOST, STOLEN, MUTILATED OR
DESTROYED WARRANT. If this Warrant is lost, stolen, mutilated or destroyed, the Company may, upon receipt of evidence satisfactory to the Company of such loss, theft, mutilation or destruction and on such terms as
to indemnity or otherwise as it may reasonably impose (which shall, in the case of a mutilated Warrant, include the surrender thereof), issue a new Warrant of like denomination and tenor as the Warrant so lost, stolen, mutilated or destroyed in
exchange for and in place of and on surrender and cancellation of the mutilated Warrant or in lieu of and in substitution for the lost, destroyed or stolen Warrant. 

15.    NOTICES, ETC. All notices required or permitted hereunder shall be in
writing and shall be deemed effectively given: (a) upon personal delivery to the party to be notified, (b) when sent by confirmed telex or facsimile if sent during normal business hours of the recipient, if not, then on the next business
day, (c) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) day after deposit with a nationally recognized overnight courier, specifying next day
delivery, with written verification of receipt. All communications shall be sent to the Company at the address listed on the signature page and to Holder at 200 First Street SW, Rochester, Minnesota 55905-0001, or at such other address as the
Company or Holder may designate by ten (10) days advance written notice to the other parties hereto. 

16.    ACCEPTANCE. Receipt of this Warrant by the Holder shall constitute acceptance of and
agreement to all of the terms and conditions contained herein. 
 17.    GOVERNING
LAW. This Warrant and all rights, obligations and liabilities hereunder shall be governed by the laws of the State of New York, specifically excluding its
choice-of-law principles. 

  
 - 7 - 

 IN WITNESS
WHEREOF, the Company has caused this Warrant to be executed by its duly authorized officer as of February 1, 2013. 
  

			
	GENOMEDX BIOSCIENCES INC.
		
	By:	 	 /s/ D. Matthews

	Name:	 	D. Matthews
	Title:	 	CFO
	Address:	 	311 Water Street, 4th Floor,
		 	Vancouver, B.C., Canada, V6B 1A1
	
	Accepted and Agreed:
	
	MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
		
	By:	 	 /s/ Daniel D. Estes

	Name:	 	Daniel D. Estes
	Title:	 	Assistant Treasurer
	Address:	 	200 First Street SW,
		 	Rochester, MN 55905

 SCHEDULE A 

ADOPTION AGREEMENT 

This Adoption Agreement (“Adoption Agreement”) is executed on February 1, 2013, by the undersigned (the
“Holder”) pursuant to the terms of that certain Voting Agreement dated as of December 2, 2011 (the “Agreement”), by and among the Company and certain of its Shareholders, as such Agreement may be amended or
amended and restated hereafter. Capitalized terms used but not defined in this Adoption Agreement shall have the respective meanings ascribed to such terms in the Agreement. By the execution of this Adoption Agreement, the Holder agrees as follows.

 1.1    Acknowledgement. Holder acknowledges that Holder is acquiring, pursuant to the terms of
a warrant agreement, certain rights to purchase shares of the Company (the “Rights”), for one of the following reasons (Check the correct box): 
  

	 	☐	 as a transferee of Shares from a party in such party’s capacity as an “Investor” bound by the
Agreement, and after such transfer, Holder shall be considered an “Investor” and a “Shareholder” for all purposes of the Agreement. 

  

	 	☐	 as a transferee of Shares from a party in such party’s capacity as a “Key Holder” bound by
the Agreement, and after such transfer, Holder shall be considered a “Key Holder” and a “Shareholder” for all purposes of the Agreement. 

  

	 	☐	 as a new Investor in accordance with Section 5.1(a) of the Agreement, in which
case Holder will be an “Investor” and a “Shareholder” for all purposes of the Agreement. 

  

	 	☒	 in accordance with Section 5.l(b) of the Agreement, as a new party who is not a
new Investor, in which case Holder will be a “Shareholder” for all purposes of the Agreement. 

1.2    Agreement. Holder hereby (a) agrees that the Rights, and any other shares or securities
required by the Agreement to be bound thereby, shall be bound by and subject to the terms of the Agreement and (b) adopts the Agreement with the same force and effect as if Holder were originally a party thereto. 

1.3    Notice. Any notice required or permitted by the Agreement shall be given to Holder at the
address or facsimile number listed below Holder’s signature hereto. 
 Accepted and Agreed: 

 

									
	MAYO FOUNDATION FOR MEDICAL	 		 	GENOMEDX BIOSCIENCES INC.
	EDUCATION AND RESEARCH	 		 		 	
					
	 By:
	 	 /s/ Daniel D. Estes
	 		 	 By:
	 	 /s/ D. Matthews

	 Name:
	 	 Daniel D. Estes
	 		 	 Name:
	 	 D. Matthews

	 Title:
	 	 Assistant Treasurer
	 		 	 Title:
	 	 CFO

	 Address:
	 	 200 first Street SW,
	 		 	 Address:
	 	 311 Water Street, 4th Floor,

		 	 Rochester, MN 55905
	 		 		 	 Vancouver, B.C., Canada V6B 1A1

 NOTICE OF EXERCISE 

TO: GENOMEDX BIOSCIENCES, INC. 

(1)    ☐     The undersigned hereby elects to purchase
                 Class A common shares (“Common Shares”) in the capital of GenomeDX Biosciences Inc. (the “Company”) pursuant to the terms of
the attached Warrant, and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any. 

☐    The undersigned hereby elects to purchase
                 Common Shares of the Company pursuant to the terms of the net exercise provisions set forth in Section 3 of the attached Warrant, and shall tender
payment of all applicable transfer taxes, if any. 
 (2)    Please issue a certificate or
certificates representing said Common Shares in the name of the undersigned or in such other name as is specified below: 
  

			
	 Name:
	  	  

	 Address:
	  	  

		  	  

 (3)    The undersigned represents that (i) the aforesaid
Common Shares are being acquired for the account of the undersigned for investment and not with a view to, or for resale in connection with, the distribution thereof and that the undersigned has no present intention of distributing or reselling such
shares; (ii) the undersigned is aware of the Company’s business affairs and financial condition and has acquired sufficient information about the Company to reach an informed and knowledgeable decision regarding its investment in the
Company; (iii) the undersigned is experienced in making investments of this type and has such knowledge and background in financial and business matters that the undersigned is capable of evaluating the merits and risks of this investment and
protecting the undersigned’s own interests; (iv) the undersigned understands that the Common Shares issuable upon exercise of this Warrant have not been registered under the Securities Act of 1933, as amended (the “Securities
Act”) or qualified by prospectus under Canadian securities laws, by reason of a specific exemption from the registration provisions of the Securities Act and pursuant to Canadian securities laws, which exemption depends upon, among other
things, the bona fide nature of the investment intent as expressed herein, and, because such securities have not been registered under the Securities Act or qualified under Canadian securities laws, they must be held indefinitely unless subsequently
registered under the Securities Act, qualified by prospectus under Canadian securities laws or an exemption from such registration or qualification is available; (v) the undersigned is aware that the aforesaid Common Shares may not be sold
pursuant to Rule 144 adopted under the Securities Act (“Rule 144”) unless certain conditions are met and until the undersigned has held the Common Shares for the number of years prescribed by Rule 144, that among the conditions for use of
Rule 144 is the availability of current information to the public about the Company and the Company has not made such information available and has no present plans to do so; and (vi) the undersigned agrees not to make any disposition of all or
any part of the aforesaid Common Shares unless and until there is then in effect a registration statement under the Securities Act or prospectus pursuant to Canadian securities laws covering such proposed disposition and such disposition is made in
accordance with said registration statement or prospectus, as applicable, or the undersigned has provided the Company with an opinion of counsel satisfactory to the Company, stating that such registration or qualification is not required. 

 

					
	  
	 		 	  

	 (Date)
	 		 	 (Signature)

			
		 		 	  

		 		 	 (Print name)EX-4.4

 Exhibit 4.4 

EXECUTION VERSION 

DECIPHER BIOSCIENCES, INC. 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made as of May 15,
2020 (the “Effective Date”), by and among DECIPHER BIOSCIENCES, INC., a Delaware corporation (the “Company”), and each of the investors listed on Schedule
A attached hereto (each, an “Investor,” and collectively, the “Investors”). 
 RECITALS

 WHEREAS, the Company and certain Investors are parties to that certain Amended and Restated Investors’ Rights Agreement,
dated March 29, 2019 (the “Prior Agreement”); 
 WHEREAS, certain of the Investors (the “Series 4
Investors”) have agreed to purchase from the Company, and the Company has agreed to sell to the Series 4 Investors, shares of Series 4 Preferred (as defined below) on the terms and conditions set forth in the Series 4 Preferred Stock and
Note Purchase Agreement dated of even date herewith, by and among the Company and the Series 4 Investors (the “Purchase Agreement”); 

WHEREAS, the obligations in the Purchase Agreement are conditioned upon the execution and delivery of this Agreement; 

WHEREAS, Section 6.7 of the Prior Agreement provides that the Prior Agreement may be amended only with the
written consent of the Company and the holders of at least a majority of the Registrable Securities (as defined in the Prior Agreement) outstanding immediately prior to the execution of this Agreement; and 

WHEREAS, the parties to the Prior Agreement desire to amend and restate the Prior Agreement and accept the rights and covenants hereof
in lieu of their rights and covenants under the Prior Agreement. 
 NOW, THEREFORE, the parties hereby agree as follows: 

1. Definitions. For purposes of this Agreement: 

1.1 “Affiliate” and its correlative terms mean, with respect to any specified Person, any other Person who, directly or
indirectly, controls, is controlled by, or is under common control with such Person, including, without limitation, any general partner, managing member, investment adviser, officer, trustee or director of such Person or any venture capital fund or
registered investment company now or hereafter existing that is controlled by one or more general partners or managing members of, or shares the same management company or investment adviser with, such Person. 

1.2 “Certificate of Incorporation” means the Company’s Amended and Restated Certificate of Incorporation, as amended
from time to time. 
 1.3 “Common Stock” means the Company’s Common Stock, par value $0.0001 per share. 

  
 1. 

 1.4 “Damages” means any loss, damage, or liability (joint or several) to
which a party hereto may become subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, or liability (or any action in respect thereof) arises out of or is based upon (i) any untrue
statement or alleged untrue statement of a material fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto; (ii) an
omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; or (iii) any violation or alleged violation by the indemnifying party (or any of its
agents or Affiliates) of the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law. 

1.5 “Derivative Securities” means any securities or rights convertible into, or exercisable or exchangeable for (in each
case, directly or indirectly), Common Stock, including options and warrants. 
 1.6 “Exchange Act” means the Securities
Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. 
 1.7 “Excluded Registration”
means (i) a registration relating to the sale of securities to employees of the Company or a subsidiary pursuant to a stock option, stock purchase, employee benefit or similar plan; (ii) a registration relating to a corporate
reorganization or other SEC Rule 145 transaction; (iii) a registration on any registration form that does not permit secondary sales; (iv) a registration on any form that does not include substantially the same information as would be
required to be included in a registration statement covering the sale of the Registrable Securities; or (v) a registration relating to the offer and sale of debt securities and/or Common Stock issuable upon conversion of those debt securities.

 1.8 “Exempted Securities” has the meaning given to such term in the Certificate of Incorporation. 

1.9 “Form S-1” means such form under the Securities Act as in effect on the date
hereof or any successor registration form under the Securities Act subsequently adopted by the SEC. 
 1.10 “Form S-3” means such form under the Securities Act as in effect on the date hereof or any successor or similar registration form under the Securities Act subsequently adopted by the SEC that permits
incorporation of substantial information by reference to other documents filed by the Company with the SEC. 
 1.11 “GAAP”
means generally accepted accounting principles in the United States. 
 1.12 “Holder” means any holder of Registrable
Securities who is a party to this Agreement. 
 1.13 “Immediate Family Member” means a child, stepchild, grandchild,
parent, stepparent, grandparent, spouse, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-

  
 2. 

 
law, brother-in-law, or
sister-in-law, including adoptive relationships, of a natural person referred to herein. 

1.14 “Initiating Holders” means, collectively, Holders who properly initiate a registration request under this Agreement.

 1.15 “IPO” means the Company’s first underwritten public offering of its Common Stock under the Securities Act.

 1.16 “Key Employee” means any executive-level employee (including division director and vice president-level positions)
as well as any employee who, either alone or in concert with others, develops, invents, programs, or designs any Company Intellectual Property (as defined in the Purchase Agreement). 

1.17 “Major Investor” means any Investor that, individually or together with such Investor’s Affiliates, holds at least
2,200,000 shares of Preferred Stock (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification effected after the date hereof). 

1.18 “Majority Preferred Directors” means the affirmative vote or written consent by at least a majority of the Preferred
Directors. 
 1.19 “New Securities” means, collectively, equity securities of the Company, whether or not currently
authorized, as well as rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable into or exercisable for such equity securities. 

1.20 “Novalis” means Novalis LifeSciences Investments I, L.P. and its Affiliates. 

1.21 “Person” means any individual, corporation, partnership, trust, limited liability company, association or other entity.

 1.22 “Preferred Directors” has the meaning given to it in the Voting Agreement. 

1.23 “Preferred Stock” means, collectively, the Company’s Series 1 Preferred Stock, the Company’s Series 2
Preferred Stock, the Company’s Series 3 Preferred Stock (“Series 3 Preferred”) and the Company’s Series 4 Preferred Stock (“Series 4 Preferred”). 

1.24 “Preferred Stockholders” means the holders of Preferred Stock and “Preferred Stockholder” means any one
of them. 
 1.25 “Qualified Initial Public Offering” has the meaning set forth in the Certificate of Incorporation. 

1.26 “Registrable Securities” means (i) the Common Stock issuable or issued upon conversion of the Preferred Stock;
(ii) any Common Stock, or any Common Stock issued or issuable (directly or indirectly) upon conversion and/or exercise of any other securities of the 

  
 3. 

 
Company, acquired by the Investors after the date hereof; and (iii) any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is
issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the shares referenced in clauses (i) and (ii) above; excluding in all cases, however, any Registrable Securities sold by a Person in a
transaction in which the applicable rights under this Agreement are not assigned pursuant to Section 6.1, and excluding for purposes of Section 2 any shares for which registration rights have terminated pursuant to
Section 2.13 of this Agreement. Notwithstanding the foregoing, the Company shall in no event be obligated to register any Preferred Stock, and Holders of Registrable Securities will not be required to convert their
Preferred Stock into Common Stock in order to exercise the registration rights granted hereunder, until immediately before the closing of the offering to which the registration relates. 

1.27 “Registrable Securities then outstanding” means the number of shares determined by adding the number of shares of
outstanding Common Stock that are Registrable Securities and the number of shares of Common Stock issuable (directly or indirectly) pursuant to then exercisable and/or convertible securities that are Registrable Securities. 

1.28 “Restricted Securities” means the securities of the Company required to bear the legend set forth in
Section 2.12(b). 
 1.29 “SEC” means the United States Securities and Exchange Commission. 

1.30 “SEC Rule 144” means Rule 144 promulgated by the SEC under the Securities Act. 

1.31 “SEC Rule 145” means Rule 145 promulgated by the SEC under the Securities Act. 

1.32 “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 1.33 “Selling Expenses” means all underwriting discounts, selling commissions, and stock transfer taxes applicable to
the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel borne and paid by the Company as provided in Section 2.6. 

1.34 “Tekla Funds” means, collectively, Tekla Healthcare Investors, Tekla Life Sciences Investors, Tekla World Healthcare
Fund, Tekla Healthcare Opportunities Fund and/or any Affiliates of the foregoing. 
 1.35 “Voting Agreement” means that
certain Amended and Restated Voting Agreement, by and among the Company, the Investors and certain stockholders of the Company of even date herewith. 

2. Registration Rights. The Company covenants and agrees as follows: 

  
 4. 

 2.1 Demand Registration. 

(a) Form S-1 Demand. If (i) at any time after five (5) years after
July 20, 2018, the Company receives a request from Holders of a majority of the Registrable Securities then outstanding, that the Company file a Form S-1 registration statement with respect to Registrable
Securities then outstanding having an anticipated aggregate offering price of at least $20,000,000 or, if earlier, (ii) at any time after one hundred eighty (180) days after the effective date of the registration statement for the IPO, the
Company receives a request from Holders of at least thirty percent (30%) of the Registrable Securities then outstanding, that the Company file a Form S-1 registration statement with respect to Registrable
Securities then outstanding having an anticipated aggregate offering price of at least $10,000,000, then, in each case, the Company shall (a) within ten (10) days after the date such request is given, give notice thereof (the
“Demand Notice”) to all Holders other than the Initiating Holders; and (b) as soon as practicable, and in any event within sixty (60) days after the date such request is made by the Initiating Holders, file a Form S-1 registration statement under the Securities Act covering all Registrable Securities that the Initiating Holders requested to be registered and any additional Registrable Securities requested to be included in
such registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days after the date the Demand Notice is given, and in each case, subject to the limitations of
Section 2.1(c) and Section 2.3. 
 (b) Form
S-3 Demand. If at any time when it is eligible to use a Form S-3 registration statement, the Company receives a request from Holders of at least twenty-five
percent (25%) of the Registerable Securities then outstanding that the Company file a Form S-3 registration statement with respect to Registrable Securities then outstanding, of such Holders having an
anticipated aggregate offering price, net of selling expenses, of at least $3,000,000, then the Company shall (i) within ten (10) days after the date such request is given, give a Demand Notice to all Holders other than the Initiating
Holders; and (ii) as soon as practicable, and in any event within forty-five (45) days after the date such request is made by the Initiating Holders, file a Form S-3 registration statement under the
Securities Act covering all Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days after the date the Demand Notice is
given, and in each case, subject to the limitations of Section 2.1(c) and Section 2.3. 

(c) Notwithstanding the foregoing obligations, if the Company furnishes to Holders requesting a registration pursuant to this
Section 2.1 a certificate signed by the Company’s Chief Executive Officer or other most senior executive officer stating that in the good faith judgment of the Company’s Board of Directors (the “Board of
Directors”) it would be materially detrimental to the Company and its stockholders for such registration statement to be filed in the near future and that it is, therefore, in the best interests of the Company to defer the filing of such
registration statement, then the Company shall have the right to defer taking action with respect to such filing, and any time periods with respect to filing or effectiveness thereof shall be tolled correspondingly, for a period of not more than
ninety (90) days after the request of the Initiating Holders is given; provided, however, that the Company may not invoke this right more than once in any twelve (12) month period; and provided further, that the Company
shall not register any securities for its own account or that of any other stockholders during such ninety (90) day period other than an Excluded Registration. 

  
 5. 

 (d) The Company shall not be obligated to effect, or to take any action to effect, any
registration pursuant to Section 2.1(a): (i) during the period that is within ninety (90) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is one hundred eighty (180) days
after the effective date of, a Company-initiated registration; provided, that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; (ii) after the
Company has effected two registrations pursuant to Section 2.1(a); or (iii) if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form S-3 pursuant to a request made pursuant to Section 2.1(b). The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Section 2.1(b) (i)
during the period that is within thirty (30) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is ninety (90) days after the effective date of, a Company-initiated registration;
provided, that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; or (ii) if the Company has effected one registration at the request of Holders of
Registrable Securities pursuant to Section 2.1(b) within the twelve (12) month period immediately preceding the date of such request. A registration shall not be counted as “effected” for purposes of this
Section 2.1(d) until such time as the applicable registration statement has been declared effective by the SEC, unless the Initiating Holders withdraw their request for such registration, elect not to pay the registration
expenses therefor, and forfeit their right to one demand registration statement pursuant to Section 2.6, in which case such withdrawn registration statement shall be counted as “effected” for purposes of this
Section 2.1(d). 
 2.2 Company Registration. If the Company proposes to register (including, for this
purpose, a registration effected by the Company for stockholders other than the Holders) any Common Stock under the Securities Act in connection with the public offering of such securities solely for cash (other than in an Excluded Registration),
the Company shall, at such time, promptly give each Holder notice of such registration. Upon the request of each Holder given within twenty (20) days after such notice is given by the Company, the Company shall, subject to the provisions of
Section 2.3, use its commercially reasonable efforts to include in such registration all of the Registrable Securities that each such Holder has requested to be included in such registration. The Company shall have the
right to terminate or withdraw any registration initiated by it under this Section 2.2 before the effective date of such registration, whether or not any Holder has elected to include Registrable Securities in such
registration. The expenses (other than Selling Expenses) of such withdrawn registration shall be borne by the Company in accordance with Section 2.6. 

2.3 Underwriting Requirements. 

(a) If, pursuant to Section 2.1, the Initiating Holders intend to distribute the Registrable Securities
covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Section 2.1, and the Company shall include such information in the Demand Notice. The
underwriter(s) will be selected by the Company and shall be reasonably acceptable to at least a fifty-five percent (55%) in interest of the Initiating Holders. In such event, the right of any Holder to include such Holder’s Registrable
Securities in such registration shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing
to distribute their securities through such underwriting shall (together with the Company as provided in Section 2.4(e)) enter into an 

  
 6. 

 
underwriting agreement in customary form with the underwriter(s) selected for such underwriting. Notwithstanding any other provision of this Section 2.3, if the managing
underwriter(s) advise(s) the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten, then the Initiating Holders shall so advise all Holders of Registrable Securities that otherwise would
be underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be allocated among such Holders of Registrable Securities, including the Initiating Holders, in proportion (as nearly as
practicable) to the number of Registrable Securities owned by each Holder or in such other proportion as shall mutually be agreed to by all such selling Holders; provided, however, that the number of Registrable Securities held by the Holders
to be included in such underwriting shall not be reduced unless all other securities of the Company are first entirely excluded from the underwriting. To facilitate the allocation of shares in accordance with the above provisions, the Company or the
underwriters may round the number of shares allocated to any Holder to the nearest one hundred (100) shares. 
 (b) In connection with
any offering involving an underwriting of shares of the Company’s capital stock pursuant to Section 2.2, the Company shall not be required to include any of the Holders’ Registrable Securities in such underwriting
unless the Holders accept the terms of the underwriting as agreed upon between the Company and its underwriters, and then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by
the Company. If the total number of securities, including Registrable Securities, requested by stockholders to be included in such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their
reasonable discretion determine is compatible with the success of the offering, then the Company shall be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters and the
Company in their sole discretion determine will not jeopardize the success of the offering. If the underwriters determine that less than all of the Registrable Securities requested to be registered can be included in such offering, then the
Registrable Securities that are included in such offering shall be allocated among the selling Holders in proportion (as nearly as practicable to) to the number of Registrable Securities (regardless of class) owned by each selling Holder or in such
other proportions as shall mutually be agreed to by all such selling Holders. To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to
the nearest one hundred (100) shares. Notwithstanding the foregoing, in no event shall (i) the number of Registrable Securities included in the offering be reduced unless all other securities (other than securities to be sold by the
Company) are first entirely excluded from the offering or (ii) the number of Registrable Securities included in the offering be reduced below thirty percent (30%) of the total number of securities included in such offering, unless such offering
is the IPO, in which case the selling Holders may be excluded further if the underwriters make the determination described above and no other stockholder’s securities are included in such offering. For purposes of the provision in this
Section 2.3(b) concerning apportionment, for any selling Holder that is a partnership, limited liability company, corporation or other entity, the partners, members, retired partners, retired members, stockholders, and
Affiliates of such Holder, or the estates and Immediate Family Members of any such partners, retired partners, members, and retired members and any trusts for the benefit of any of the foregoing Persons, shall be deemed to be a single “selling
Holder,” and any pro rata reduction with respect to such “selling Holder” shall be based upon the aggregate number of Registrable Securities owned by all Persons included in such “selling Holder,” as defined in this
sentence. 

  
 7. 

 (c) For purposes of Section 2.1, a registration shall not be
counted as “effected” if, as a result of an exercise of the underwriter’s cutback provisions in Section 2.3(a), fewer than fifty percent (50%) of the total number of Registrable Securities that
Holders have requested to be included in such registration statement are actually included. 
 2.4 Obligations of the Company.
Whenever required under this Section 2 to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 

(a) prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its commercially reasonable
efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement effective for a period of up to one hundred
twenty (120) days or, if earlier, until the distribution contemplated in the registration statement has been completed; provided, however, that (i) such one hundred twenty (120) day period shall be extended for a period of time
equal to the period the Holder refrains, at the request of an underwriter of Common Stock (or other securities) of the Company, from selling any securities included in such registration, and (ii) in the case of any registration of Registrable
Securities on Form S-3 that are intended to be offered on a continuous or delayed basis, subject to compliance with applicable SEC rules, such one hundred twenty (120) day period shall be extended for up
to sixty (60) days, if necessary, to keep the registration statement effective until all such Registrable Securities are sold; 
 (b)
prepare and file with the SEC such amendments and supplements to such registration statement, and the prospectus used in connection with such registration statement, as may be necessary to comply with the Securities Act in order to enable the
disposition of all securities covered by such registration statement for the period set forth in Section 2.4(a); 

(c) furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as required by the Securities
Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities; 

(d) use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other
securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided, however, that the Company shall not be required to qualify to do business or to file
a general consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

(e) in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and
customary form, with the underwriter(s) of such offering, provided such underwriting agreement contains reasonable and customary provisions, and provided further, that each Holder participating in such underwriting shall also enter
into and perform its obligations under such an agreement; 

  
 8. 

 (f) use its commercially reasonable efforts to cause all such Registrable Securities
covered by such registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued by the Company are then listed; 

(g) provide a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and provide a CUSIP number
for all such Registrable Securities, in each case not later than the effective date of such registration; 
 (h) promptly make available
for inspection by the selling Holders, any managing underwriter(s) participating in any disposition pursuant to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling
Holders, all financial and other records, pertinent corporate documents, and properties of the Company, and cause the Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any
such seller, underwriter, attorney, accountant, or agent, in each case, as necessary or advisable to verify the accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith; 

(i) notify each selling Holder, promptly after the Company receives notice thereof, of the time when such registration statement has been
declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and 
 (j) after such
registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend or supplement such registration statement or prospectus. 

2.5 Furnish Information. It shall be a condition precedent to the obligations of the Company to take any action pursuant to this
Section 2 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the Registrable Securities held by it, and the intended method of
disposition of such securities as is reasonably required to effect the registration of such Holder’s Registrable Securities. 
 2.6
Expenses of Registration. All expenses (other than Selling Expenses) incurred in connection with registrations, filings, or qualifications pursuant to Section 2, including all registration, filing, and qualification
fees; printers’ and accounting fees; fees and disbursements of counsel for the Company; and the reasonable fees and disbursements, not to exceed $50,000, of one counsel for the selling Holders (“Selling Holder Counsel”),
shall be borne and paid by the Company; provided, however, that the Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to Section 2.1 if the registration request is
subsequently withdrawn at the request of the Holders of seventy percent (70%) of the Registrable Securities to be registered (in which case all selling Holders shall bear such expenses pro rata based upon the number of Registrable Securities
that were to be included in the withdrawn registration), unless the Holders of seventy percent (70%) of the Registrable Securities agree to forfeit their right to one registration pursuant to Section 2.1(a) or
Section 2.1(b); provided further, that if, at the time of such withdrawal, the Holders shall have learned of a material adverse change in the condition, 

  
 9. 

 
business, or prospects of the Company from that known to the Holders at the time of their request and have withdrawn the request with reasonable promptness after learning of such information then
the Holders shall not be required to pay any of such expenses and shall not forfeit their right to one registration pursuant to Section 2.1(a) or Section 2.1(b). All Selling Expenses relating to Registrable Securities
registered pursuant to this Section 2 shall be borne and paid by the Holders pro rata on the basis of the number of Registrable Securities registered on their behalf. 

2.7 Delay of Registration. No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any
registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2. 

2.8 Indemnification. If any Registrable Securities are included in a registration statement under this
Section 2: 
 (a) To the extent permitted by law, the Company will indemnify and hold harmless each selling
Holder, and the partners, members, officers, directors, trustees, investment advisors and stockholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as defined in the Securities Act) for each such Holder;
and each Person, if any, who controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other
aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided that the indemnity
agreement contained in this Section 2.8(a) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Company, which consent shall not be
unreasonably withheld, nor shall the Company be liable for any Damages to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of any such
Holder, underwriter, controlling Person, or other aforementioned Person expressly for use in connection with such registration. 
 (b) To
the extent permitted by law, each selling Holder, severally and not jointly, will indemnify and hold harmless the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls
the Company within the meaning of the Securities Act, legal counsel and accountants for the Company, any underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person
of any such underwriter or other Holder, against any Damages, in each case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on
behalf of such selling Holder expressly for use in connection with such registration; and each such selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses reasonably incurred thereby in connection
with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Section 2.8(b) shall not apply
to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; and provided further, that in no

  
 10. 

 
event shall the aggregate amounts payable by any Holder by way of indemnity or contribution under Sections 2.8(b) and 2.8(d) exceed the proceeds from the offering
received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of fraud or willful misconduct by such Holder. 

(c) Promptly after receipt by an indemnified party under this Section 2.8 of notice of the commencement of any
action (including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this
Section 2.8, give the indemnifying party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying party so desires, participate
jointly with any other indemnifying party to which notice has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other indemnified
parties that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel
retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such action. The failure to give notice to the indemnifying
party within a reasonable time of the commencement of any such action shall relieve such indemnifying party of any liability to the indemnified party under this Section 2.8, to the extent that such failure materially
prejudices the indemnifying party’s ability to defend such action. The failure to give notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this
Section 2.8. 
 (d) To provide for just and equitable contribution to joint liability under the Securities Act in
any case in which either (i) any party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Section 2.8 but it is judicially determined (by the entry of a final judgment or
decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this
Section 2.8 provides for indemnification in such case, or (ii) contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this
Section 2.8, then, and in each such case, such parties will contribute to the aggregate losses, claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such proportion as
is appropriate to reflect the relative fault of each of the indemnifying party and the indemnified party in connection with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to
reflect any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or allegedly untrue statement of a material
fact, or the omission or alleged omission of a material fact, relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct
or prevent such statement or omission; provided, however, that, in any such case, (x) no Holder will be required to contribute any amount in excess of the public offering price of all such Registrable Securities offered and sold by such
Holder pursuant to such registration statement, and (y) no Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from

  
 11. 

 
any Person who was not guilty of such fraudulent misrepresentation; and provided further, that in no event shall a Holder’s liability pursuant to this
Section 2.8(d), when combined with the amounts paid or payable by such Holder pursuant to Section 2.8(b), exceed the proceeds from the offering received by such Holder (net of any Selling Expenses
paid by such Holder), except in the case of willful misconduct or fraud by such Holder. 
 (e) Notwithstanding the foregoing, to the extent
that the provisions on indemnification and contribution contained in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting
agreement shall control. 
 (f) Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten
public offering, the obligations of the Company and Holders under this Section 2.8 shall survive the completion of any offering of Registrable Securities in a registration under this Section 2, and
otherwise shall survive the termination of this Agreement. 
 2.9 Reports Under Exchange Act. With a view to making
available to the Holders the benefits of SEC Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form S-3, the Company shall: 
 (a) make and keep available adequate current public information, as those terms
are understood and defined in SEC Rule 144, at all times after the effective date of the registration statement filed by the Company for the IPO; 

(b) use commercially reasonable efforts to file with the SEC in a timely manner all reports and other documents required of the Company under
the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and 
 (c)
furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) to the extent accurate, a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any
time after ninety (90) days after the effective date of the registration statement filed by the Company for the IPO), the Securities Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or
that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any time after the Company so qualifies); (ii) a copy of the most recent annual or quarterly report of the Company and
such other reports and documents so filed by the Company; and (iii) such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that permits the selling of any such securities without
registration (at any time after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form S-3 (at any time after the Company so qualifies to use such form). 

2.10 Limitations on Subsequent Registration Rights. From and after the date of this Agreement, the Company shall not, without the prior
written consent of the Holders of a majority of the Registrable Securities then outstanding, enter into any agreement with any holder 

  
 12. 

 
or prospective holder of any securities of the Company that would (i) provide to such holder the right to include securities in any registration on other than a subordinate basis after all
Holders have had the opportunity to include in the registration and offering all shares of Registrable Securities that they wish to so include or (ii) allow such holder or prospective holder to initiate a demand for registration of any
securities held by such holder or prospective holder. 
 2.11 “Market
Stand-off” Agreement. Each Holder hereby agrees that it will not, without the prior written consent of the managing underwriter, during the period commencing on the date of the
final prospectus relating to the IPO and ending on the date specified by the Company and the managing underwriter (such period not to exceed one hundred eighty (180) days, which period may be extended upon the request of the managing
underwriter, to the extent required by any FINRA rules, for an additional period of up to fifteen (15) days if the Company issues or proposes to issue an earnings or other public release within fifteen (15) days of the expiration of the 180-day lockup period), (i) lend, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right, or warrant to purchase, or
otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable (directly or indirectly) for Common Stock held immediately before the effective date of the
registration statement for such offering or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of such securities, whether any such transaction described
in clause (i) or (ii) above is to be settled by delivery of Common Stock or other securities, in cash, or otherwise. The foregoing provisions of this Section 2.11 shall not apply to the sale of any shares to an
underwriter pursuant to an underwriting agreement, and shall be applicable to the Holders only if all officers and directors are subject to the same restrictions and the Company uses commercially reasonable efforts to obtain a similar agreement from
all stockholders individually owning more than one percent (1%) of the Company’s outstanding Common Stock (after giving effect to conversion into Common Stock of all outstanding Preferred Stock of the Company). The underwriters in connection
with such registration are intended third-party beneficiaries of this Section 2.11 and shall have the right, power, and authority to enforce the provisions hereof as though they were
a party hereto. Each Holder further agrees to execute such agreements as may be reasonably requested by the underwriters in connection with such registration that are consistent with this Section 2.11 or that are necessary
to give further effect thereto. Any discretionary waiver or termination of the restrictions of any or all of such agreements by the Company or the underwriters shall apply pro rata to all Holders subject to such agreements, based on the number of
shares subject to such agreements, provided that this sentence shall not apply to any discretionary waiver or termination under this Section 2.11 if the aggregate number of released shares does not exceeds one percent (1%) of the total
outstanding voting shares of the Company. 
 2.12 Restrictions on Transfer. 

(a) The Preferred Stock and the Registrable Securities shall not be sold, pledged, or otherwise transferred, and the Company shall not
recognize and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except upon the conditions specified in this Agreement, which conditions are intended to ensure compliance with the
provisions of the Securities Act. A transferring Holder will cause any proposed purchaser, pledgee, or transferee of the Preferred Stock and the Registrable Securities 

  
 13. 

 
held by such Holder to agree to take and hold such securities subject to the provisions and upon the conditions specified in this Agreement. 

(b) Each certificate or instrument representing (i) the Preferred Stock, (ii) the Registrable Securities, and (iii) any other
securities issued in respect of the securities referenced in clauses (i) and (ii), upon any stock split, stock dividend, recapitalization, merger, consolidation, or similar event, shall (unless otherwise permitted by the provisions of
Section 2.12(c)) be stamped or otherwise imprinted with a legend substantially in the following form (in addition to any legends required by applicable securities laws and/or a legend restricting resale of such securities):

  

					
		  	 THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 OR THE SECURITIES LAWS OF ANY STATE, AND
HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF, AND MAY BE OFFERED, SOLD, ASSIGNED, PLEDGED, TRANSFERRED OR OTHERWISE DISPOSED OF IN THE UNITED STATES ONLY PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 OR PURSUANT TO AN APPLICABLE EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933 AND, IF REQUESTED BY DECIPHER BIOSCIENCES, INC. (THE “COMPANY”), UPON DELIVERY OF AN OPINION
OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY AND ITS COUNSEL THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933.
  

THE SECURITIES REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER, A COPY OF WHICH
IS ON FILE WITH THE SECRETARY OF THE COMPANY.
	  	

 The Holders consent to the Company making a notation in its records and giving instructions to any transfer agent of the
Restricted Securities in order to implement the restrictions on transfer set forth in this Section 2.12. 
 (c)
The holder of each certificate representing Restricted Securities, by acceptance thereof, agrees to comply in all respects with the provisions of this Section 2. Before any proposed sale, pledge, or transfer of any
Restricted Securities, unless there is in effect a registration statement under the Securities Act covering the proposed transaction, the Holder thereof shall give notice to the Company of such Holder’s intention to effect such sale, pledge, or
transfer. Each such notice shall describe the manner and circumstances of the proposed sale, pledge, or transfer in sufficient detail and, if reasonably requested by the Company, shall be accompanied at such Holder’s expense by either
(i) a written opinion of legal counsel who shall, and whose legal opinion shall, be reasonably satisfactory to the Company, addressed to the Company, to the effect that the proposed transaction may be effected without registration under the
Securities Act; (ii) a “no action” letter from the SEC to the effect that the proposed sale, pledge, or transfer of such Restricted Securities without registration will not result in a recommendation

  
 14. 

 
by the staff of the SEC that action be taken with respect thereto; or (iii) any other evidence reasonably satisfactory to counsel to the Company to the effect that the proposed sale, pledge,
or transfer of the Restricted Securities may be effected without registration under the Securities Act, whereupon the Holder of such Restricted Securities shall be entitled to sell, pledge, or transfer such Restricted Securities in accordance with
the terms of the notice given by the Holder to the Company. The Company will not require such a legal opinion or “no action” letter in any transaction in which such Holder distributes Restricted Securities to an Affiliate of such Holder
for no consideration or transfers such Restricted Securities to an Affiliate(s) in connection with a reallocation of such Restricted Securities among such Affiliates, whether with or without consideration; provided that each transferee agrees
in writing to be subject to the terms of this Section 2.12. Each certificate or instrument evidencing the Restricted Securities transferred as above provided shall bear, except if such transfer is made pursuant to SEC
Rule 144, the appropriate restrictive legend set forth in Section 2.12(b), except that such certificate shall not bear such restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend
is not required in order to establish compliance with any provisions of the Securities Act. 
 2.13 Termination of Registration
Rights. The right of any Holder to request registration or inclusion of Registrable Securities in any registration pursuant to Section 2.1 or Section 2.2 shall terminate upon the earliest to
occur of: 
 (a) as to such Holder, upon the sale of all shares held by such Holder pursuant to an effective registration statement under
the Securities Act. 
 (b) as to such Holder, such earlier time after the IPO at which such Holder (i) can sell all shares held by it
in compliance with Rule 144(b)(1)(i) or (ii) holds one percent (1%) or less of the Company’s outstanding Common Stock and all Registrable Securities held by such Holder (together with any Affiliate of the Holder with whom such Holder must
aggregate its sales under Rule 144) can be sold without limitation in any three (3)-month period without registration in compliance with Rule 144; or 

(c) the fifth (5th) anniversary of the consummation of the IPO. 

3. Information and Observer Rights. 

3.1 Delivery of Financial Statements. The Company shall deliver to each Major Investor, provided that the Board of Directors has
not reasonably determined that such Major Investor is a competitor of the Company: 
 (a) as soon as practicable, but in any event within
one hundred eighty (180) days after the end of each fiscal year of the Company or such later date as may be approved by the Majority Preferred Directors, (i) a balance sheet as of the end of such year, (ii) statements of income and of
cash flows for such year, and a comparison between (x) the actual amounts as of and for such fiscal year and (y) the comparable amounts for the prior year and as included in the Budget (as defined in
Section 3.1(e)) for such year, with an explanation of any material differences between such amounts and a schedule as to the sources and applications of funds for such year, and (iii) a statement of stockholders’
equity as of the end of such year, all such financial statements 

  
 15. 

 
audited and certified by independent public accountants of nationally recognized standing selected by the Company; 

(b) as soon as practicable, but in any event within forty-five (45) days after the end of each of the first three (3) quarters of
each fiscal year of the Company, unaudited statements of income and of cash flows for the portion of the fiscal year ending on the expiry of such fiscal quarter, and a comparison between (x) the actual amounts as of and for such period and
(y) the comparable amounts for the same period in the prior fiscal year and as included in the Budget, and an unaudited balance sheet and a statement of stockholders’ equity as of the end of such fiscal quarter, all prepared in accordance
with GAAP (except that such financial statements may (i) be subject to normal year-end audit adjustments and (ii) not contain all notes thereto that may be required in accordance with GAAP); 

(c) as soon as practicable, upon request by a Major Investor, a statement showing the number of shares of each class and series and
securities convertible into or exercisable for shares outstanding at the end of the most recently completed fiscal quarter, the Common Stock issuable upon conversion or exercise of any outstanding securities convertible or exercisable for Common
Stock and the exchange ratio or exercise price applicable thereto, and the number of shares of issued stock options and stock options not yet issued but reserved for issuance, if any, all in sufficient detail as to permit the Major Investors to
calculate their respective percentage equity ownership in the Company; 
 (d) as soon as practicable, but in any event within thirty
(30) days after the end of each month or such later date as may be approved by the Majority Preferred Directors, unaudited statements of income and of cash flows for such month, and an unaudited balance sheet as of the end of such month,
all prepared in accordance with GAAP (except that such financial statements may (i) be subject to normal year-end audit adjustments and (ii) not contain all notes thereto that may be required in
accordance with GAAP); 
 (e) (i) as soon as practicable, but in any event thirty (30) days before the end of each fiscal year, a
draft budget and business plan for the next fiscal year prepared on a monthly basis, including balance sheets, income statements, and statements of cash flow for such months (collectively, the “Budget”), (ii) as soon as practicable,
but in any event within fifteen (15) days after the end of each such fiscal year, a final Budget approved by the Board of Directors in accordance with Section 5.4(f) hereof, and (iii) any other budgets or revised budgets
prepared by the Company and approved by the Board of Directors, promptly following such approval by the Board of Directors; and 
 (f) such
other information relating to the financial condition, business, prospects, or corporate affairs of the Company as any Major Investor may from time to time reasonably request; provided, however, that the Company shall not be obligated under
this Section 3.1 to provide information (i) that the Company reasonably determines in good faith to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in form
acceptable to the Company) (ii), the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel, or (iii) if the Company has reasonably determined that such Major Investor is a competitor of the
Company. 

  
 16. 

 If, for any period, the Company has any subsidiary whose accounts are consolidated with those of the
Company, then in respect of such period the financial statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the Company and all such consolidated subsidiaries. 

Notwithstanding anything else in this Section 3.1 to the contrary, the Company may cease providing the information set forth in this
Section 3.1 during the period starting with the date thirty (30) days before the Company’s good-faith estimate of the date of filing of a registration statement if it reasonably concludes it must do so to comply
with the SEC rules applicable to such registration statement and related offering; provided that the Company’s covenants under this Section 3.1 shall be reinstated at such time as the Company is no longer
actively employing its commercially reasonable efforts to cause such registration statement to become effective. 
 3.2 Inspection.
The Company shall permit each Major Investor or its authorized representatives (provided that the Board of Directors has not reasonably determined that such Major Investor is a competitor of the Company), at such Major Investor’s
expense, to visit and inspect the Company’s properties; examine its books of account and records; and discuss the Company’s affairs, finances, and accounts with its officers, during normal business hours of the Company as may be reasonably
requested by the Major Investor; provided, however, that the Company shall not be obligated pursuant to this Section 3.2 to provide access to any information that it reasonably and in good faith considers to be a
trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in form acceptable to the Company) or the disclosure of which would adversely affect the attorney-client privilege between the Company and its
counsel. 
 3.3 Observer Rights. As long as Novalis continues to hold any shares of Preferred Stock, the Company shall invite one
(1) individual designated by Novalis (the “Novalis Observer”) to attend all meetings of its Board of Directors in a nonvoting observer capacity and, in this respect, shall give the Novalis Observer copies of all notices,
minutes, consents, and other materials that it provides to its directors at the same time and in the same manner as provided to such directors; provided, however, that the Novalis Observer shall agree to hold in confidence and trust
and to act in a fiduciary manner with respect to all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude the Novalis Observer from any meeting or portion thereof
if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or a conflict of interest, or if Novalis or the Novalis
Observer is a competitor of the Company. 
 3.4 Confidentiality. Each Investor agrees that such Investor will keep confidential and
will not disclose, divulge, or use for any purpose (other than to monitor its investment in the Company) any confidential information obtained from the Company pursuant to the terms of this Agreement (including notice of the Company’s intention
to file a prospectus or registration statement), unless such confidential information (a) is known or becomes known to the public in general (other than as a result of a breach of this Section 3.4 by such Investor),
(b) is or has been independently developed or conceived by the Investor without use of the Company’s confidential information, or (c) is or has been made known or disclosed to the Investor by a third party without a breach of any
obligation of confidentiality such third party may have to the 

  
 17. 

 
Company; provided, however, that an Investor may disclose confidential information (i) to its attorneys, accountants, consultants, and other professionals to the extent necessary to
obtain their services in connection with monitoring its investment in the Company or, to the extent necessary in connection with an Investor’s tax filings, financial reporting or accounting matters (including any required filings with the SEC);
(ii) to any prospective purchaser of any Registrable Securities from such Investor, if such prospective purchaser agrees to be bound by the provisions of this Section 3.4; (iii) to any Affiliate, or current or prospective
partner, member or stockholder, or wholly owned subsidiary of such Investor in the ordinary course of business, or in connection with fund raising activity or reporting activity of the kind customarily provided with respect to investment activity
that is undertaken in the ordinary course of the business of the Investor, provided that such Investor informs such Person that such information is confidential and directs such Person to maintain the confidentiality of such information; or
(iv) as may otherwise be required by law, provided that the Investor promptly notifies the Company of such disclosure and takes reasonable steps to minimize the extent of any such required disclosure. 

3.5 Termination of Information and Observer Rights. The covenants set forth in Sections 3.1,
3.2 and 3.3 shall terminate and be of no further force or effect upon the consummation of the Qualified Initial Public Offering. 

4. Rights to Future Stock Issuances and Securities. 

4.1 Right of First Offer. Subject to the terms and conditions of this Section 4.1 and applicable securities
laws, if the Company proposes to offer or sell any New Securities, the Company shall first offer such New Securities to each Preferred Stockholder. Each Preferred Stockholder shall be entitled to apportion the right of first offer hereby granted to
it among itself and its Affiliates in such proportions as it deems appropriate. 
 (a) The Company shall give notice (the “Offer
Notice”) to each Preferred Stockholder, stating (i) its bona fide intention to offer such New Securities, (ii) the number of such New Securities to be offered, and (iii) the price and terms, if any, upon which it proposes to
offer such New Securities. 
 (b) By notification to the Company within twenty (20) days after the Offer Notice is given, each
Preferred Stockholder may elect to purchase or otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals the proportion that the Common Stock issued and held, or issuable
(directly or indirectly) upon conversion or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held, by such Preferred Stockholder bears to the total Common Stock of the Company then outstanding (assuming full
conversion or exercise, as applicable, of all Preferred Stock and other Derivative Securities). At the expiration of such twenty (20) day period, the Company shall promptly notify each Preferred Stockholder that elects to purchase or acquire
all the shares available to it (each, a “Fully Exercising Investor”) of any other Preferred Stockholder’s failure to do likewise. During the ten (10) day period commencing after the Company has given such notice, each
Fully Exercising Investor may, by giving notice to the Company, elect to purchase or acquire, in addition to the number of shares specified above, up to that portion of the New Securities for which Preferred Stockholders were entitled to subscribe
but that were not subscribed for by the Preferred Stockholders which is equal to the proportion that 

  
 18. 

 
the Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of Preferred Stock and any other Derivative Securities then held, by such
Fully Exercising Investor bears to the Common Stock issued and held, or issuable (directly or indirectly) upon conversion or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held, by all Fully
Exercising Investors who wish to purchase such unsubscribed New Securities. The closing of any sale pursuant to this Section 4.1(b) shall occur within the later of one hundred twenty (120) days after the date that the
Offer Notice is given and the date of initial sale of New Securities pursuant to Section 4.1(c). 
 (c) If all New Securities
referred to in the Offer Notice are not elected to be purchased or acquired as provided in Section 4.1(b), the Company may, during the ninety (90) day period following the expiration of the periods provided in
Section 4.1(b), offer and sell the remaining unsubscribed portion of such New Securities to any Person or Persons at a price not less than, and upon terms no more favorable to the offeree than, those specified in the Offer
Notice. If the Company does not enter into an agreement for the sale of the New Securities within such period, or if such agreement is not consummated within thirty (30) days after the execution thereof, the right provided hereunder shall be
deemed to be revived and such New Securities shall not be offered unless first reoffered to the Preferred Stockholders in accordance with this Section 4.1. 

(d) The right of first offer in this Section 4.1 shall not be applicable to (i) Exempted Securities;
(ii) shares of Common Stock issued in the IPO; or (iii) the issuance of shares of Series 4 Preferred to purchasers pursuant to the Purchase Agreement. 

4.2 Termination. The covenants set forth in Section 4.1 shall terminate and be of no further force or effect
upon the consummation of the Qualified Initial Public Offering. 
 5. Additional Covenants. 

5.1 Insurance. The Company shall maintain, from financially sound and reputable insurers Directors and Officers liability insurance, in
an amount not less than $3,000,000 (or such higher amount as may be agreed to by the Majority Preferred Directors) and on terms and conditions satisfactory to the Board of Directors until such time as the Board of Directors determines that such
insurance should be discontinued. The policy shall not be cancelable by the Company without prior approval by the Board of Directors, including the Majority Preferred Directors. 

5.2 Employee Agreements. The Company will cause (i) each person now or hereafter employed by it or by any subsidiary (or engaged
by the Company or any subsidiary as a consultant/independent contractor) with access to confidential information and/or trade secrets to enter into a nondisclosure and proprietary rights assignment agreement and (ii) each Key Employee to enter
into a one (1) year noncompetition and nonsolicitation agreement, substantially in the form approved by the Board of Directors. In addition, the Company shall not amend, modify, terminate, waive, or otherwise alter, in whole or in part, any of
the above-referenced agreements or any restricted stock agreement between the Company and any employee, without the approval of the Board of Directors, including the Majority Preferred Directors. 

  
 19. 

 5.3 Employee Stock. Unless otherwise approved by the Board of Directors,
including the Majority Preferred Directors, all future employees and consultants of the Company who purchase, receive options to purchase, or receive awards of shares in the capital of the Company after the date hereof shall be required to execute
restricted stock or option agreements, as applicable, providing for (i) vesting of shares over a four (4) year period, with the first twenty-five percent (25%) of such shares vesting following twelve (12) months of continued
employment or service, and the remaining shares vesting in equal monthly installments over the following thirty-six (36) months, and (ii) a market stand-off
provision substantially similar to that in Section 2.11. In addition, unless otherwise approved by the Board of Directors, including the Majority Preferred Directors, the Company shall retain a “right of first
refusal” on employee transfers until the Qualified Initial Public Offering, and shall have the right to repurchase unvested shares at cost upon termination of employment of a holder of restricted stock. 

5.4 Matters Requiring Majority Preferred Directors’ Approval. The Company hereby covenants and agrees with each of
the Investors that it shall not (and shall cause any of its direct or indirect subsidiaries to not), without approval of a majority of the Board of Directors, including the Majority Preferred Directors: 

(a) approve any sale, license, pledge, encumbrance, or other transfer of any intellectual property, other than licenses, pledges or
encumbrances in the ordinary course of business; 
 (b) enter into material contracts affecting the Company’s right to compete in the
industry in which it operates; 
 (c) enter into joint ventures or partnerships or establish
non-wholly owned subsidiaries; 
 (d) incur any additional indebtedness for borrowed money
following the date of this Agreement in excess of $1,000,000 in the aggregate; 
 (e) appoint or remove the Chief Executive Officer or the
Chief Financial Officer; 
 (f) approve the Budget (including any material amendments thereto); 

(g) change the Company’s current line of business in any material respect, enter into new lines of business or exit the current line of
business; or 
 (h) adopt or amend employment contracts or benefit plans for the Company’s senior management. 

5.5 Board Matters; Committees. Unless otherwise determined by the vote of a majority of the directors then in office, the Board
of Directors shall meet at least four (4) times per year in accordance with an agreed-upon schedule. The Company shall reimburse the non-employee directors and the Novalis Observer for all reasonable out-of-pocket travel expenses incurred (consistent with the Company’s travel policy, if any) in connection with attending meetings of the Board of Directors and
committees of the Board of Directors of which any such 

  
 20. 

 
director is a member and attending other Company events at the Company’s request. The Company will maintain, an audit and compensation committee, each of which shall consist solely of non-management directors and shall include the Majority Preferred Directors; provided, that a Preferred Director shall not be required to serve on any such committee to the extent such director is not willing
or able to so serve. The Preferred Directors shall be entitled to sit on any committee of the Board of Directors, and the board of directors (or similar body) of any subsidiary of the Company. 

5.6 Successor Indemnification. If the Company or any of its successors or assignees consolidates with or merges into any other Person
and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall be made so that the successors and assignees of the Company assume the obligations of the Company with
respect to indemnification of members of the Board of Directors as in effect immediately before such transaction, whether such obligations are contained in the Certificate of Incorporation or elsewhere, as the case may be. 

5.7 Termination of Covenants. The covenants set forth in this Section 5, except for
Section 5.6, shall terminate and be of no further force or effect upon the consummation of a Qualified Initial Public Offering. 

5.8 Additional Purchasers. The Parties to this Agreement specifically acknowledge and agree that the Company may issue additional
shares of Series 4 Preferred after the date of this Agreement pursuant to the Purchase Agreement; provided that such additional purchasers execute a counterpart to this Agreement and become a party hereto. 

6. Miscellaneous. 
 6.1
Successors and Assigns. The rights under this Agreement may only be assigned (and only with all related obligations) by a Holder to a transferee of Registrable Securities that (i) is an Affiliate of a Holder; (ii) is a
Holder’s Immediate Family Member or trust for the benefit of an individual Holder or one or more of such Holder’s Immediate Family Members; or (iii) after such transfer, holds at least 150,000 shares of Registrable Securities (subject
to appropriate adjustment for stock splits, stock dividends, combinations, and other recapitalizations); provided, however, that (x) the Company is, within a reasonable time after such transfer, furnished with written notice of the name
and address of such transferee and the Registrable Securities with respect to which such rights are being transferred; and (y) such transferee agrees in a written instrument delivered to the Company to be bound by and subject to the terms and
conditions of this Agreement, including the provisions of Section 2.11. For the purposes of determining the number of shares of Registrable Securities held by a transferee, the holdings of a transferee (1) that is an Affiliate or
stockholder of a Holder; (2) who is a Holder’s Immediate Family Member; or (3) that is a trust for the benefit of an individual Holder or such Holder’s Immediate Family Member shall be aggregated together and with those of the
transferring Holder; provided further, that all transferees who would not qualify individually for assignment of rights shall have a single attorney-in-fact for
the purpose of exercising any rights, receiving notices, or taking any action under this Agreement. The terms and conditions of this Agreement inure to the benefit of and are binding upon the respective successors and permitted assignees of the
parties. Nothing in this Agreement, express or implied, is intended to confer upon any party 

  
 21. 

 
other than the parties hereto or their respective successors and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly
provided herein. 
 6.2 Governing Law. This Agreement shall be governed by, and construed in accordance with, the laws of the State
of Delaware, regardless of the laws that might otherwise govern under applicable principles of conflicts of law. 
 6.3 Currency. All
references to currency in this Agreement are to United States dollars unless otherwise specifically indicated. 
 6.4
Counterparts; Facsimile. This Agreement may be executed and delivered by facsimile transmission or electronic mail (including in .pdf format) and in two or more counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument. 
 6.5 Titles and Subtitles. The titles and subtitles used in this Agreement
are for convenience only and are not to be considered in construing or interpreting this Agreement. 
 6.6 Notices. All notices and
other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given upon the earlier of actual receipt or: (i) personal delivery to the party to be notified; (ii) when sent, if sent by
electronic mail or facsimile during the recipient’s normal business hours, and if not sent during normal business hours, then on the recipient’s next business day; (iii) five (5) days after having been sent by registered or certified
mail, return receipt requested, postage prepaid; or (iv) one (1) business day after the business day of deposit with a nationally recognized overnight courier, freight prepaid, specifying next-day
delivery, with written verification of receipt. All communications shall be sent to the respective parties at their addresses as set forth on Schedule A hereto, or to the principal office of the Company and to the attention
of the President or Chief Executive Officer, in the case of the Company, or to such email address, facsimile number, or address as subsequently modified by written notice given in accordance with this Section 6.6. 

6.7 Amendments and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived
(either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company and the holders of a majority of the Registrable Securities then outstanding, including the Series 3-4 Requisite Holders (as defined in the Certificate of Incorporation); provided that the Company may in its sole discretion waive compliance with Section 2.12(c) (and the
Company’s failure to object promptly in writing after notification of a proposed assignment allegedly in violation of Section 2.12(c) shall be deemed to be a waiver); and provided further, that any provision
hereof may be waived by any waiving party on such party’s own behalf, without the consent of any other party. Notwithstanding the foregoing, this Agreement may not be amended or terminated and the observance of any term hereof may not be waived
with respect to any Investor without the written consent of such Investor, unless such amendment, termination, or waiver applies to all Investors in the same fashion (it being agreed that a waiver of the provisions of
Section 4 with respect to a particular transaction shall be deemed to apply to all Investors in the same fashion if such waiver 

  
 22. 

 
does so by its terms, notwithstanding the fact that certain Investors may nonetheless, by agreement with the Company, purchase securities in such transaction). 

The Company shall give prompt notice of any amendment or termination hereof or waiver hereunder to any party hereto that did not consent in writing to such
amendment, termination, or waiver. Any amendment, termination, or waiver effected in accordance with this Section 6.7 shall be binding on all parties hereto, regardless of whether any such party has consented thereto or
received notice thereof. No waivers of or exceptions to any term, condition, or provision of this Agreement, in any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such term, condition, or
provision. 
 6.8 Severability. In case any one or more of the provisions contained in this Agreement is for any reason held to be
invalid, illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid, illegal, or unenforceable provision shall be reformed and construed so that
it will be valid, legal, and enforceable to the maximum extent permitted by law. 
 6.9 Aggregation of Stock. All shares of
Registrable Securities held or acquired by Affiliates shall be aggregated together for the purpose of determining the availability of any rights under this Agreement and such Affiliated persons may apportion such rights as among themselves in any
manner they deem appropriate. 
 6.10 Entire Agreement. This Agreement (including any Schedules and Exhibits hereto) constitutes the
full and entire understanding and agreement among the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties is expressly canceled. The Prior
Agreement is superseded by the terms of this Agreement. 
 6.11 Delays or Omissions. No delay or omission to exercise any right,
power, or remedy accruing to any party under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such non-breaching or non-defaulting party, nor shall it be construed to be a waiver of or acquiescence to any such breach or default, or to any similar breach or default thereafter occurring, nor shall any waiver of any single breach or
default be deemed a waiver of any other breach or default theretofore or thereafter occurring. All remedies, whether under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative. 

6.12 Acknowledgment. The Company acknowledges that certain Investors and their Affiliated advisers and funds are registered investment
companies, professional investment advisers, managers and/or funds and, as such, engage in the business of venture capital investing, among other things, and therefore review the business plans and related proprietary information of many
enterprises, including enterprises which may have products or services which compete directly or indirectly with those of the Company. Nothing in this Agreement shall preclude or in any way restrict such Investors or their Affiliated advisers and
funds from investing or participating in any particular enterprise whether or not such enterprise has products or services which compete with those of the Company. The Company acknowledges and agrees that the Tekla

  
 23. 

 
Funds shall not be deemed to be competitors of the Company for purposes of this Agreement solely as a result of such activities. 

6.13 Tekla Funds. A copy of the Declaration of Trust, as amended and restated, for each of Tekla Healthcare Investors, Tekla Life
Sciences Investors, Tekla Healthcare Opportunities Fund and Tekla World Healthcare Fund is on file with the Secretary of State of The Commonwealth of Massachusetts, and notice is hereby given that this Agreement is executed on behalf of the Tekla
Funds by an officer or trustee of the Tekla Funds in his or her capacity as an officer or trustee of the Tekla Funds, and not individually and that the obligations of or arising out of this Agreement are not binding upon any of the trustees,
officers or shareholders individually but are binding only upon the assets and property of each of the respective Tekla Funds. 

[Remainder of Page Intentionally Left Blank] 

  
 24. 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	COMPANY:
	
	DECIPHER BIOSCIENCES, INC.
		
	By:	 	/s/ Tina S. Nova, Ph.D.
	Name:	 	Tina S. Nova, Ph.D.
	Title:	 	President and Chief Executive Officer

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

			
	ALBANY PRIVATE EQUITY PTY LTD.
		
	By:	 	/s/ Peter Hall
	Name: Peter Hall
	Title: Director

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

	
	 AYOUNG JUN

	
	 /s/ Ayoung Jun

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

			
	B.C. CAPITAL LTD.
		
	By:	 	/s/ Brian Cooper
	Name: Brian Cooper
	Title: Chairman

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

			
	BARRY D. PLOST
		
	By:	 	/s/ Barry D. Plost

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

			
	CD-VENTURE GMBH
		
	By:	 	/s/ Dirk Wilken
	Name: Dirk Wilken
	Title: Managing Director

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

			
	CRG PARTNERS III – PARALLEL FUND “A” L.P.
	 BY: CRG PARTNERS III – PARALLEL FUND “A” GP L.P.

ITS: GENERAL PARTNER

	 BY: CRG PARTNERS III – PARALLEL FUND “A” GP LLC

ITS: GENERAL PARTNER

		
	By:	 	/s/ Nathan Hukill
	Name: Nathan Hukill
	Title: Authorized Signatory

  

			
	Witness:	 	/s/ Nicole Nesson
	Name:	 	Nicole Nesson

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

			
	CRG PARTNERS III – PARALLEL FUND “B”
(CAYMAN) L.P.
	 BY: CRG PARTNERS III (CAYMAN) GP L.P.

ITS: GENERAL PARTNER

	 BY: CRG PARTNERS III GP LLC

ITS: GENERAL PARTNER

		
	By:	 	/s/ Nathan Hukill
	Name: Nathan Hukill
	Title: Authorized Signatory

  

			
	Witness:	 	/s/ Nicole Nesson
	Name:	 	Nicole Nesson

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

	
	 CRG PARTNERS III (CAYMAN) LEV AIV I L.P.

    BY: CRG PARTNERS III –(CAYMAN) GP L.P.

    ITS: GENERAL PARTNER

        BY: CRG PARTNERS III GP LLC

        ITS: GENERAL PARTNER 

 
			
		
	By:	 	/s/ Nathan Hukill

 
			
	Name:	 	Nathan Hukill

 
			
	Title:	 	Authorized Signatory

 
			
		
	Witness:	 	/s/ Nicole Nesson
	Name:	 	Nicole Nesson

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

	
	 CRG PARTNERS III (CAYMAN) UNLEV AIV I L.P.

    BY: CRG PARTNERS III –(CAYMAN) GP L.P.

    ITS: GENERAL PARTNER

        BY: CRG PARTNERS III GP LLC

        ITS: GENERAL PARTNER 

 
			
		
	By:	 	/s/ Nathan Hukill

 
			
	Name:	 	Nathan Hukill

 
			
	Title:	 	Authorized Signatory

 
			
		
	Witness:	 	/s/ Nicole Nesson
	Name:	 	Nicole Nesson

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

	
	 CRG PARTNERS III L.P.

    BY: CRG PARTNERS III GP L.P.

    ITS: GENERAL PARTNER

        BY: CRG PARTNERS III GP LLC

        ITS: GENERAL PARTNER 

 
			
		
	By:	 	/s/ Nathan Hukill

 
			
	Name:	 	Nathan Hukill

 
			
	Title:	 	Authorized Signatory

 
			
		
	Witness:	 	/s/ Nicole Nesson

 
			
	Name:	 	    Nicole Nesson

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

			
	D PARKES OPERA INC.

 
			
		
	 By:
	 	/s/ David Parkes

 
			
	Name:	 	David Parkes

 
			
	Title:	 	Sole Director and Authorized Signatory

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

			
	EITAN SHAPIRO

 
			
		
	By:	 	 /s/ Eitan Shapiro

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

			
	ERIC LIEW

 
			
		
	 By:
	 	/s/ Eric Liew

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

			
	GORDON AND LISA BENNETT

 
			
		
	 By:
	 	/s/ Gordon Bennett

 
			
	Name:	 	Gordon Bennett

 
			
		
	By:	 	/s/ Lisa Bennett

 
			
	Name:	 	Lisa Bennett

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

			
	IAN GOLD

 
			
		
	 By:
	 	/s/ Ian Gold

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

			
	JEFFREY ZACKON

 
			
		
	 By:
	 	/s/ Jeffrey Zackon

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

			
	KBO HOLDINGS LTD.

 
			
		
	 By:
	 	/s/ Gordon Bennett

 
			
	Name:	 	Gordon Bennett

 
			
	Title:	 	Sole Director and Authorized Signatory

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

			
	MARC AND MARA DWORSKY LIVING TRUST
		
	By:	 	/s/ Marc Dworsky
	Name:	 	Marc Dworsky
	Title:	 	Trustee
	
	MARC DWORSKY 
		
	By:	 	/s/ Marc Dworsky
	Name:	 	Marc Dworsky

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

			
	MICHAEL F. CROWLEY II AND CHRISTINE N. CROWLEY

 
			
		
	By:	 	/s/ Michael F. Crowley II

 
			
	Name:	 	Michael F. Crowley II

 
			
		
	By:	 	/s/ Christine N. Crowley

 
			
	Name:	 	Christine N. Crowley

 
			
	
	 MICHAEL F. CROWLEY

 
			
		
	By:	 	/s/ Michael F. Crowley II

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

			
	MSD HUMAN HEALTH HOLDING BV

 
			
		
	By:	 	/s/ P.R. Koopman

 
			
	Name:	 	P.R. Koopman

 
			
	Title:	 	Director

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

			
	NOVALIS LIFESCIENCES INVESTMENTS I, L.P.
	BY:	 	NOVALIS LIFESCIENCES INVESTMENTS I GP, LLC                            
	ITS:	 	GENERAL PARTNER                                
		
	By:	 	/s/ Marijn E. Dekkers
	Name:	 	Marijn E. Dekkers
	Title:	 	Manager

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

			
	OMER GALIN
		
	 By:
	 	/s/ Omer Galin

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

			
	SHAPIRO SHOW LTD.
		
	By:	 	/s/ Eitan Shapiro
	Name:	 	Eitan Shapiro
	Title:	 	Chairman

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

			
	SHMULIK ZYSMAN
		
	 By:
	 	/s/ Shmulik Zysman

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

			
	TEKLA HEALTHCARE INVESTORS*
		
	By:	 	/s/ Daniel R. Omstead
	Name:	 	Daniel R. Omstead
	Title:	 	President

  

	*	 The name Tekla Healthcare Investors is the designation of the Trustees for the time being under a Declaration
of Trust dated February 20, 1992, as amended, and all persons dealing with Tekla Healthcare Investors must look solely to the trust property for the enforcement of any claim against Tekla Healthcare Investors, as neither the Trustees, officers
nor shareholders assume any personal liability for the obligations entered into on behalf of Tekla Healthcare Investors. 

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

			
	TEKLA HEALTHCARE OPPORTUNITIES FUND*
		
	By:	 	/s/ Daniel R. Omstead
	Name:	 	Daniel R. Omstead
	Title:	 	President

  

	*	 The name Tekla Healthcare Opportunities Fund is the designation of the Trustees for the time being under a
Declaration of Trust dated February 20, 1992, as amended, and all persons dealing with Tekla Healthcare Opportunities Fund must look solely to the trust property for the enforcement of any claim against Tekla Healthcare Opportunities Fund, as
neither the Trustees, officers nor shareholders assume any personal liability for the obligations entered into on behalf of Tekla Healthcare Opportunities Fund. 

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

			
	TEKLA LIFE SCIENCES INVESTORS*
		
	By:	 	/s/ Daniel R. Omstead
	Name:	 	Daniel R. Omstead
	Title:	 	President

  

	*	 The name Tekla Life Sciences Investors is the designation of the Trustees for the time being under a
Declaration of Trust dated February 20, 1992, as amended, and all persons dealing with Tekla Life Sciences Investors must look solely to the trust property for the enforcement of any claim against Tekla Life Sciences Investors, as neither the
Trustees, officers nor shareholders assume any personal liability for the obligations entered into on behalf of Tekla Life Sciences Investors. 

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

			
	TEKLA WORLD HEALTHCARE FUND*

 
			
		
	 By:
	 	/s/ Daniel R. Omstead

 
			
	Name:	 	Daniel R. Omstead

 
			
	Title:	 	President

  

	*	 The name Tekla World Healthcare Fund is the designation of the Trustees for the time being under a Declaration
of Trust dated February 20, 1992, as amended, and all persons dealing with Tekla World Healthcare Fund must look solely to the trust property for the enforcement of any claim against Tekla World Healthcare Fund, as neither the Trustees,
officers nor shareholders assume any personal liability for the obligations entered into on behalf of Tekla World Healthcare Fund. 

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

			
	THE MOSS FAMILY TRUST DATED DECEMBER 22, 2004

 
			
		
	By:	 	/s/ Gillian Moss

 
			
	 Name:
	 	Gillian Moss

 
			
	 Title:
	 	Trustee

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

			
	UNITEDHEALTH GROUP VENTURES, LLC

 
			
		
	 By:
	 	/s/ Rob Webb

 
			
	Name:	 	Rob Webb

 
			
	Title:	 	President

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

			
	YONGCHENG (CAYMAN) LIMITED

 
			
		
	 By:
	 	 /s/ Dong Jiaming

			
	Name:	 	Dong Jiaming

 
			
	Title:	 	Director

  

			
	YONGHUA INTERNATIONAL II L.P.

 
			
		
	 By:
	 	/s/ Huang Ting

 
			
	Name:	 	Huang Ting

 
			
	Title:	 	Authorised Signatory of the General Partner

  

			
	YH NORTH AMERICA CAPITAL L.P.

 
			
		
	 By:
	 	/s/ Huang Ting

 
			
	Name:	 	Huang Ting

 
			
	Title:	 	Authorised Signatory of the General Partner

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 SCHEDULE A 

INVESTORS 
  

	
	 Investor Name

	Albany Private Equity Pty Ltd.
	Ayoung Jun
	B.C. Capital Ltd.
	Barry D. Plost
	Barry Shaked
	CD-VENTURE GmbH
	Cosmic Network Limited
	 CRG Partners III – Parallel Fund “A” L.P.

CRG Partners III – Parallel Fund “B” (Cayman) L.P.

CRG Partners III Cayman Lev AIV I L.P.

CRG Partners III Cayman Unlev AIV I L.P.

CRG Partners III L.P.

	D Parkes Opera Inc.
	Eitan Shapiro
	Eric Liew
	EVP Technology Fund III GmbH & Co KG
	Gordon and Lisa Bennett
	Ian Gold
	Jeffrey Zackon
	KBO Holdings Ltd.
	 Marc and Mara Dworsky Living Trust December 1, 2008

Marc Dworsky

	 Michael F. Crowley

Michael F. Crowley II and Christine N. Crowley

	MSD Human Health Holding BV
	Nathan Schaffer
	Novalis LifeSciences Investments I, L.P.
	Omer Galin
	Rostan Gamma Limited
	Sarah Marel-Schaffer
	Shapiro Show Ltd.
	Shipley Family Chatham Trust
	Shmulik Zysman
	 Tekla Healthcare Investors

Tekla Healthcare Opportunities Fund

Tekla Life Sciences Investors

Tekla World Healthcare Fund

	The Moss Family Trust dated December 22, 2004
	UnitedHealth Group Ventures, LLC
	YH North America Capital L.P.
	 Yongcheng (Cayman) Limited

Yonghua International II L.P.

  
 A-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}]]